Larotrectinib is a selective inhibitor of tropomyosin receptor kinases (TrkA, TrkB, and TrkC) indicated for the treatment of solid tumors featuring NTRK gene fusions or rearrangements in patients who have… Read more
![Chemical structure of (2R)-2-(2,5-Difluorophenyl)-1-(3-((S)-3-hydroxypyrrolidine-1-carboxamido)pyrazolo[1,5-a]pyrimidin-5-yl)pyrrolidine 1-oxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2R-2-25-Difluorophenyl-1-3-S-3-hydroxypyrrolidine-1-carboxamidopyrazolo15-apyrimidin-5-ylpyrrolidine-1-oxide.png&w=3840&q=75)

![Chemical structure of (R)-5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)-3-nitropyrazolo[1,5-a]pyrimidine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1223404-90-7-R-5-2-25-Difluorophenylpyrrolidin-1-yl-3-nitropyrazolo15-apyrimidine.png&w=3840&q=75)
![Chemical structure of (R)-5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-amine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1223404-88-3-R-5-2-25-Difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidin-3-amine.png&w=3840&q=75)
![Chemical structure of (R)-5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1223404-89-4-R-5-2-25-Difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidine.png&w=3840&q=75)
![Chemical structure of (R)-N-(5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydro-1H-pyrrole-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2699151-02-3-R-N-5-2-25-Difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidin-3-yl-23-dihydro-1H-pyrrole-1-carboxamide.png&w=3840&q=75)
![Chemical structure of (R)-N-(5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydro-1H-pyrrole-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FR-N-5-2-25-Difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidin-3-yl-23-dihydro-1H-pyrrole-1-carboxamide.png&w=3840&q=75)


![Chemical structure of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxy-N-nitrosopyrrolidine-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FS-N-5-R-2-25-Difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidin-3-yl-3-hydroxy-N-nitrosopyrrolidine-1-carboxamide.png&w=3840&q=75)
![Chemical structure of (S)-N-(5-Chloropyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2226370-52-9-S-N-5-Chloropyrazolo15-apyrimidin-3-yl-3-hydroxypyrrolidine-1-carboxamide.png&w=3840&q=75)
![Chemical structure of 1,3-Bis(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)urea](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F13-Bis5-R-2-25-difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidin-3-ylurea.png&w=3840&q=75)





Larotrectinib is a selective inhibitor of tropomyosin receptor kinases (TrkA, TrkB, and TrkC) indicated for the treatment of solid tumors featuring NTRK gene fusions or rearrangements in patients who have exhausted other treatment options. This category provides a comprehensive range of high-quality materials to support the analysis of this potent antineoplastic agent. Laboratories rely on these reference standards, which include the active pharmaceutical ingredient, process-related impurities, potential degradation products, and stable isotope-labelled compounds, to ensure precise pharmaceutical characterization. By utilizing these materials for impurity profiling, method validation, and rigorous quality control testing, researchers can accurately quantify drug substance integrity and monitor stability throughout development and manufacturing. The inclusion of stable isotope-labelled standards further facilitates sensitive and specific analytical quantification, such as in liquid chromatography-mass spectrometry, supporting robust regulatory compliance and consistency in pharmaceutical testing workflows.